BioCentury
ARTICLE | Strategy

CAR dealing

How J&J’s deal for Legend’s anti-BCMA CAR will shape its cell therapy strategy

January 6, 2018 1:06 AM UTC

Johnson & Johnson’s deal with Legend Biotech will net the pharma both an anti-BCMA CAR T therapy and a partner to help shape its cell therapy strategy.

J&J chose the Chinese company’s LCAR-B38M as its first chimeric antigen receptor (CAR) T cell product, and as a first step in what is likely to be a measured approach using partnerships to build knowledge and capabilities for optimizing cell therapies for cancer...